RB1 and neoplasm: Conversely, treatment with a TGFβ signaling inhibitor reduced ZEB1 and SNAI2 levels and prevented the acquisition of mesenchymal marker expression and morphological features, thus linking mesenchymal differentiation in Rb with enhanced tumor cell invasion through the TGFβ/ZEB1/SNAI2 axis.